Immunotherapy Clinical Trials

168 recruitingLast updated: June 17, 2026

There are 168 actively recruiting immunotherapy clinical trials across 28 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Guangzhou, Guangdong, China, Shanghai, Shanghai Municipality, China, Shanghai, China. Updated daily from ClinicalTrials.gov.


Immunotherapy Trials at a Glance

168 actively recruiting trials for immunotherapy are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Shanghai. Lead sponsors running immunotherapy studies include Sun Yat-sen University, Shanghai Juncell Therapeutics, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse immunotherapy trials by phase

Treatments under study

About Immunotherapy Clinical Trials

Looking for clinical trials for Immunotherapy? There are currently 115 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 168 trials

Recruiting
Phase 2

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Consolidation ImmunotherapyChemoradiotherapyLimited-stage Small Cell Lung Cancer (LS-SCLC)+1 more
Shanghai Chest Hospital28 enrolled1 locationNCT07091305
Recruiting
Not Applicable

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

Non-small Cell Lung CancerExercise TrainingImmunotherapy+1 more
Medical University of Graz50 enrolled1 locationNCT07267000
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Phase 1

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

Solid TumorsImmunotherapyCold Exposure+1 more
West China Hospital24 enrolled1 locationNCT07538479
Recruiting
Phase 2

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Bladder CancerImmunotherapyLiquid Biopsy
Tianjin Medical University Second Hospital53 enrolled3 locationsNCT07475403
Recruiting
Phase 3

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

Rectal CancerRadiotherapyImmunotherapy+1 more
Tao Zhang444 enrolled1 locationNCT07113275
Recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Nasopharyngeal CarcinomaMulti-omics TechniqueRecurrent and Metastatic Nasopharyngeal Carcinoma+1 more
Sun Yat-sen University50 enrolled1 locationNCT06197776
Recruiting
Not Applicable

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

PainCancerStress+2 more
University of California, Irvine12 enrolled2 locationsNCT07581080
Recruiting
Phase 1

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Solid Tumor CancerSolid Tumor Cancer Treatment With Immunotherapy
Jun Zhou90 enrolled6 locationsNCT07584954
Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting
Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055
Recruiting
Phase 2

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Head and Neck Squamous Cell CarcinomaTargeted TherapyImmunotherapy+1 more
West China Hospital98 enrolled1 locationNCT07040956
Recruiting
Phase 2

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Colorectal, CancerRadiotherapyTargeted Therapy+2 more
Shandong Cancer Hospital and Institute62 enrolled1 locationNCT06356584
Recruiting

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment

RadiotherapyImmunotherapySmall Cell Lung Cancer ( SCLC )+1 more
Shanghai Chest Hospital500 enrolled1 locationNCT07565532
Recruiting
Phase 1

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Acute Myeloid LeukemiaMaintenance TherapyPersonalized Active Immunotherapy
Fujian Medical University Union Hospital90 enrolled1 locationNCT07551037
Recruiting

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

CancerQuality of LifeDistress, Emotional+4 more
Taipei Veterans General Hospital, Taiwan200 enrolled1 locationNCT06461780
Recruiting

IMMUNO-FIT Observational Study

Quality of LifeNeoplasmsImmunotherapy+2 more
University Hospital Southampton NHS Foundation Trust67 enrolled1 locationNCT07354971
Recruiting
Phase 2

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

ChemotherapyRectal CancerRadiotherapy+1 more
Tao Zhang25 enrolled1 locationNCT07239466
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568